SCHEMBL7651650

SCHEMBL7651650

CCOC(=O)/C(C)=C/c1ccc(Br)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.76
MAPT P10636 8/20 0.76
MEN1 O00255 6/20 0.76
LMNA P02545 4/20 0.76
NPSR1 Q6W5P4 3/20 0.76
S1PR4 O95977 1/20 0.76
S1PR1 P21453 1/20 0.76
MAPK1 P28482 1/20 0.76
PTGS2 P35354 1/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4E B2RXH2 3/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 2/20 0.44
HSP90AA1 P07900 1/20 0.44
NR1H4 Q96RI1 1/20 0.43
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7030290 1.00 KMT2A (0.76) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL3609468 0.88 MAPT (0.58) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL3609471 0.88 MAPT (0.58) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL1673521 0.86 KMT2A (1.00) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL5617201 0.86 KMT2A (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL321922 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL10885404 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL10564181 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL12035802 0.86 KMT2A (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL14358911 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034121-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2025-01-30 US disclosed
EP-4419511-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS Nanjing Immunophage Biotech Co., Ltd (CN) 2024-08-28 EP disclosed
CN-118201911-A Compounds and their use as GPR183 inhibitors 南京艾美斐生物医药科技有限公司 2024-06-14 CN disclosed
WO-2023066190-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2023-04-27 WO disclosed
WO-2023066190-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2023-04-27 WO disclosed
US-6399824-B1 FOR THERAPY AND PROPHYLAXIS OF ARRHYTHMIAS, CARDIAC INFRACTION, ISCHEMIC CONDITIONS, ANGINA PECTORIS, SHOCK, FOR PRESERVING AND STORING A TRANSPLANT FOR SURGICAL MEASURE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-06-04 US disclosed
US-20020058710-A1 SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH. 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058710-A1 SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM GANC, GMPS, GCDH KMT2A 3345/4885MAPT 1593/4885MEN1 1833/4885
US-20250034121-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS GPR183, GPR180, GPR65 KMT2A 3673/4885MAPT 3530/4885MEN1 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.